Clinical trials: Liver Tumour
Colorectal Neoplasms
Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed
This study will test the safety and efficacy of TroVax in patients undergoing surgical resection of colorectal cancer with liver metastases.
- Trial name
- NCT00259844
- Testing
- TroVax
- Volunteers
- 20 people
- Sponsor
- Cancer Research UK
Hepatocellular Carcinoma
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib compared with HAIC of irinotecan, oxaliplatin…
- Trial name
- NCT03812783
- Testing
- Hepatic arterial infusion chemotherapy, Folfox Protocol, Sorafenib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Cancer of the Liver
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00422877
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- American Regent, Inc.
Liver Cancer
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00881751
- Testing
- bevacizumab, erlotinib hydrochloride, sorafenib tosylate
- Where
- 6 sites in United States
- Volunteers
- 95 people
- Sponsor
- Medical University of South Carolina
Primary Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
A multicentre, randomized, open-label, parallel-group, active controlled study.
- Trial name
- NCT02956772
- Testing
- TACE, Arsenic trioxide
- Where
- 9 sites in China
- Volunteers
- 190 people
- Sponsor
- Hunan Provincial People's Hospital
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Hepatocellular Carcinoma
Randomized Phase II Trial of Chemoembolization and Sorafenib
The study will be a single-center, randomized Phase II study of conventional TACE in combination with sorafenib, given either continuously or sequentially, in patients with unresectable HCC.
- Trial name
- NCT02908165
- Testing
- conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
- Where
- United States
- Sponsor
- Yale University
Metastatic Breast Cancer, Lung Metastases
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have…
- Conditions
- Metastatic Breast Cancer, Lung Metastases, Liver Metastases
- Trial name
- OX40 Breast (NCT01862900)
- Testing
- MEDI6469
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Providence Health & Services
Stage IIIA Hepatocellular Carcinoma
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).
- Trial name
- NCT06061445
- Testing
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
This study will evaluate the safety and efficacy of DEB-TACE with visualable embolization microspheres versus PVA microspheres for hepatocellular carcinoma.
- Trial name
- NCT06190665
- Testing
- DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres
- Where
- 2 sites in China
- Volunteers
- 188 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer Metastatic
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus…
- Trial name
- FOXFIREGlobal (NCT01721954)
- Testing
- FOLFOX6m, SIR-Spheres microspheres
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 209 people
- Sponsor
- Sirtex Medical
Cancer, Chronic Obstructive Pulmonary Disease
Comparative Trial of Home-Based Palliative Care
Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings.
- Conditions
- Cancer, Chronic Obstructive Pulmonary Disease, Heart Failure, Dementia
- Trial name
- HomePal (NCT03694431)
- Testing
- Tech-supported HBPC, Standard HBPC
- Where
- 2 sites in United States
- Volunteers
- 3,999 people
- Sponsor
- Kaiser Permanente
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
Liver Neoplasms, Hepatectomy
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
Major liver resection is associated with substantial intraoperative blood loss and subsequently blood transfusions. Blood transfusion in elective liver surgery is a significant factor of perioperative morbidity and mortality, as…
- Conditions
- Liver Neoplasms, Hepatectomy, Blood Transfusion, Blood Loss, Surgical
- Trial name
- PRICE2 (NCT03651154)
- Testing
- Hypovolemic Phlebotomy
- Where
- 4 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Ottawa Hospital Research Institute
Liver Neoplasms, Carcinoma, Hepatocellular
Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors
1. Research Background The background of this study centers on stereotactic body radiation therapy (SBRT), an advanced form of radiotherapy that is short in duration, highly effective, and easy for patients to comply with.
- Trial name
- NCT07745153
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Southern Medical University, China
Colorectal Cancer, Liver Metastasis
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy.
- Conditions
- Colorectal Cancer, Liver Metastasis, LDRT
- Trial name
- NCT06848465
- Testing
- Low Dose Radiotherapy, Short course Radiotherapy, XELOX
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Colon Cancer Liver Metastasis
Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases
Contrast-enhanced intraoperative ultrasound (CE-IOUS) during surgery for colorectal liver metastases (CLM) has become a part of clinical practice. However, if it should be selectively or routinely applied remains unclear.
- Trial name
- CEIOUSCLM (NCT01526200)
- Testing
- Contrast-enhanced intraoperative ultrasound
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- University of Milan
Malignant Tumor of Pancreas Metastatic to Liver
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure…
- Trial name
- NCT04037241
- Testing
- Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA
- Sponsor
- Sorrento Therapeutics, Inc.
Liver Cirrhosis, Hepatocellular Carcinoma
Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Surveillance
- Trial name
- NCT04414956
- Testing
- AFP-L3, AFP, PIVKA-II
- Where
- 15 sites in South Korea
- Volunteers
- 1,418 people
- Sponsor
- Korea University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.